2 Results for "

DZD8586

" in MedChemExpress (MCE) Product Catalog:
Products (2)

2 Results for "DZD8586" in MCE Product Catalog:

Cat. No.: HY-160167
CAS No.: 2662512-15-2
Synonyms: DZD8586
Target:  

Src Btk

Research Areas:  

Inflammation/Immunology Cancer

Birelentinib (DZD8586) is an orally effective, selective, non-covalent inhibitor targeting LYN tyrosine kinase and BTK tyrosine kinase, capable of penetrating the blood-brain barrier. Birelentinib exhibits concentration-dependent antiproliferative effects in RI-1 cells and diffuse large B-cell lymphoma (DLBCL) cell lines carrying BTK resistance mutations (such as C481X, V416L, etc.). Birelentinib blocks both BTK-dependent and independent signaling of the B-cell receptor (BCR), thereby inhibiting tumor cell proliferation and inducing cell death. Birelentinib can be used in research to overcome resistance to existing covalent and non-covalent BTK inhibitors in B-cell non-Hodgkin lymphoma (B-NHL) .
loading...
    loading...
Cat. No.: HY-160167A
CAS No.: 2662512-14-1
Synonyms: (R,R)-DZD8586
Target:  

Btk

Research Areas:  

Cancer

(R,R)-Birelentinib ((R,R)-DZD8586) (Compound 14) is a potent BTK inhibitor with IC50 values for BTK WT and BTK C481S of 0.7 and 0.86 nM, respectively. (R,R)-Birelentinib inhibits the self-phosphorylation of BTK and its IC50 is 24.3 nM. (R,R)-Birelentinib exhibits significant anti-proliferative activity against wild-type and C481S mutant HEK293 cells. (R,R)-Birelentinib can be used for the study of drug-resistant B-cell malignancies .
loading...
    loading...